Morepen Laboratories has received a favorable verdict from the Himachal Pradesh High Court, which quashed a Rs 117.94 crore GST recovery notice. The dispute involved alleged excess tax refunds; the court's order removes this contingent liability, providing regulatory relief to the company without impacting its current financial position or operations.
Morepen Laboratories Wins Legal Relief: High Court Quashes Rs 118 Crore SCN
Amount involved: Rs 117.94 crore.
Legal outcome: Show Cause Notice quashed by Himachal Pradesh High Court.
Reader Takeaway: The court order removes a significant contingent liability, clearing regulatory uncertainty for the company's balance sheet.
What just happened
Morepen Laboratories Limited has officially informed the stock exchanges that the Hon’ble High Court of Himachal Pradesh at Shimla has ruled in its favor. The court has quashed a Show Cause Notice (SCN) issued by the Commissioner of Central GST & Central Excise, Shimla. The notice had previously demanded the recovery of Rs 117.94 crore related to alleged excess GST refunds under the CGST Act, 2017, including interest and penalties.
Why this matters
This ruling provides critical regulatory certainty for investors. A demand of this magnitude, while classified as a contingent liability, often hangs over a company's valuation and sentiment. By quashing the notice, the High Court has effectively removed the legal threat, allowing the management to focus entirely on core operations rather than prolonged tax litigation regarding Section 54 of the CGST Act.
What changes now
The company has confirmed that there is no impact on its financials, ongoing operations, or business activities following the order dated October 12, 2026. Shareholders can view this as the closure of a significant legal hurdle that was previously disclosed in regulatory filings throughout 2025 and 2026.
What to track next
Investors should monitor the company’s upcoming quarterly filings for any final adjustments regarding the classification of these previously reported contingent liabilities. The focus will now shift back to the company's core performance in its pharmaceutical and medical devices segments.